Clinical trials
| Trial Name | Condition | Phase | Status | HTCs | Details | |
|---|---|---|---|---|---|---|
| B7841007 BASIS-OLE NCT05145127 | Severe hemophilia A or moderately severe to severe hemophilia B Age 12-75 | 3 | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca Adolescent and adult participants 12 to <75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as FVIII activity <1% or FIX activity ≤2%, respectively) with or without inhibitors |
||||||
| C0371002 BeneGene-2 NCT03861273 | Moderately severe to severe hemophilia B Males, age 18-65 | 3 | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca Adult male participants between the ages of 18 to 65 who have documented moderately severe to severe hemophilia B, defined as FIX:C ≤2%. To demonstrate the efficacy of a single infusion of PF06838435 in male participant >=18 years of age with moderately sever to sever Hemophilia B(FIXC:<=2%) |
||||||
| C0371003 NCT03307980 | Moderately severe to severe hemophilia B Males, age 18-65 | 2a | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Assessment of safety and tolerability of a single IV infusion of PF-06838435. Contact: study@htc.ca Adult male participants between the ages of 18 to 65 who have documented moderately severe to severe hemophilia B, defined as FIX:C ≤2%. The primary objective is the assessment of safety and tolerability of a single IV infusion of PF-06838435. |
||||||
| CSL222_3005 (IX-Tend) NCT06003387 | Hemophilia B; with detectable pretreatment AAV5 neutralizing antibodies | 3b | Recruiting Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca The primary objective of this study is to assess the (possible) correlation of pretreatment AAV5 NAb titers on the risk of bleeding during the 52 weeks following CSL222 treatment and the establishment of stable FIX expression (Months 7 to 18 postdose) compared to standard of care continuous routine FIX prophylaxis during the ≥ 6-month Lead-in Period. |
||||||
| EFC17574 (ATLAS-Neo) NCT03417102 | Severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX Males, age ≥ 12 | 3 | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca The purpose of this study is to measure the frequency of bleeding episodes with fitusiran prophylaxis in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX, who have switched from their prior CFC or BPA standard of care treatment. |
||||||
| LTS16294 (BIVV XTEND) NCT04644575 | Severe Hemophilia A Age ≥ 12 | 3 | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca The purpose of this study is to evaluate the efficacy of BIVV001 as prophylaxis treatment for persons with hemophilia A as well in the treatment of bleeding episodes. Other objectives of the study include the assessment of the consumption of BIVV001 required for the treatment of bleeding episodes as well as to evaluate the effect BIVV001 prophylaxis has on joint health. |
||||||
| MO42623 (Beyond-ABR) NCT05181618 | Hemophilia A Age 13-70 | 4 | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca Participants aged ≥ 13 and < 70 years with severe hemophilia A without FVIII inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis; The efficacy objectives for this study are to evaluate the impact of emicizumab treatment on joint health and HRQoL outcomes of participants with hemophilia A as well as their physical activity. The safety objective for this study is to evaluate the safety of emicizumab on the basis of incidence and severity of adverse events, injection-site reactions, and thromboembolic events; incidence of thrombotic microangiopathy, severe hypersensitivity, anaphylaxis, and anaphylactoid events. |
||||||
| NN7769-4532 Frontier 4 NCT05685238 | Hemophilia A | 3 | Closed to enrollment Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Investigate long-term safety of Mim8 prophylaxis in participants with haemophilia A with or without FVIII inhibitors. Contact: study@htc.ca Long-term safety and efficacy of Mim8 prophylaxis will be investigated in children (1−11 years of age), adolescents (12−17 years of age) and adults (≥ 18 years of age), in participants with hemophilia A with or without FVIII inhibitors. The primary objective of this study is to investigate long-term safety of Mim8 prophylaxis in participants with haemophilia A with or without FVIII inhibitors. |
||||||
| R131L1265-HEMB-2318 (BEYOND-9) NCT06379789 | Hemophilia B Males, age ≥ 18 | 1/2 | Recruiting Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca Adult male participants 18 years or older with diagnosis of severe or moderately severe hemophilia B with medical history of FIX functional activity (≤2% or <0.02 IU/mL) or documented genotype known to produce severe hemophilia B (1) To evaluate the safety and tolerability of a single intravenous administration of REGV131-LNP1265 in participants with hemophilia B. (2) To evaluate Factor IX protein (FIX) functional activity following a single intravenous administration of REGV131-LNP1265 in patients with hemophilia B. |
||||||
| SR604-1 NCT06349473 | Severe congenital Hemophilia A or severe and/or moderately severe congenital Hemophilia B Males, age 16-80 | 1 | Recruiting Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca Male participants aged 18 to 60 years, inclusive, who have one of the following bleeding disorders: Primary: To confirm the safety and tolerability of multiple ascending doses of SR604 administered Q4W as SC injections in participants with Hemophilia A or Hemophilia B. Secondary: To continue to assess the PK profile of SR604 following repeated SC injections, To assess the preliminary clinical activity of SR604, To assess the immunogenicity of SR604. |
||||||
| VGA039-CP001 (VIVID) NCT05776069 | Von Willebrand Disease Adults, age 18-60 | 1a/1b | Active but not recruiting Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca To investigate the safety and tolerability of single intravenous (IV) or subcutaneous (SC) doses of VGA039. To investigate the pharmacokinetics (PK) of single IV or SC doses of VGA039. To investigate the pharmacodynamics (PD) of single IV or SC doses of VGA039. To investigate the presence of anti-drug antibodies (ADAs) raised against VGA039 after single IV or SC doses. To investigate additional PD effects after single IV or SC doses. |
||||||
| WP44714 (NXT007) NCT05987449 | Multiple See details | 1/2 | Recruiting Last updated Jan 2026 | Hamilton Health Sciences Corporation | ||
|
Objective: Contact: study@htc.ca Part 1: Adolescent and adult male participants aged ≥12 and <60 years with severe or moderate HA on previous prophylactic or on-demand treatment with FVIII concentrate or HA with FVIII inhibitors on previous prophylactic or on-demand bypass agent (rFVIIa or aPCC) Primary objective: To evaluate the safety of multiple doses of NXT007. Secondary Objectives: (1) To characterize the pharmacokinetics of NXT007 following multiple doses of NXT007, (2) To evaluate the immunogenicity of multiple doses of NXT007, (3) To evaluate the recurrence of or de novo FVIII inhibitor occurrence, and change to FVIII inhibitor titer over time, (4) To explore the efficacy of multiple doses of NXT007. |
||||||